FY2030 EPS Estimates for RenovoRx Increased by HC Wainwright

RenovoRx, Inc. (NASDAQ:RNXT) – Stock analysts at HC Wainwright lifted their FY2030 earnings per share estimates for RenovoRx in a research report issued on Friday, May 15th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.42 for the year, up from their previous estimate of $0.39. HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for RenovoRx’s current full-year earnings is ($0.30) per share.

RenovoRx (NASDAQ:RNXT) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.47 million. RenovoRx had a negative return on equity of 135.03% and a negative net margin of 823.98%.

RNXT has been the subject of several other research reports. Ascendiant Capital Markets lifted their price target on shares of RenovoRx from $13.00 to $13.50 and gave the company a “buy” rating in a research note on Thursday, April 9th. JonesTrading raised shares of RenovoRx to a “strong-buy” rating in a research note on Thursday, January 29th. Finally, Wall Street Zen downgraded shares of RenovoRx from a “hold” rating to a “strong sell” rating in a research note on Saturday, April 4th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

RenovoRx Price Performance

Shares of NASDAQ RNXT opened at $0.81 on Monday. The company has a market cap of $36.35 million, a P/E ratio of -2.44 and a beta of 1.00. RenovoRx has a 1 year low of $0.70 and a 1 year high of $1.45. The firm has a 50-day simple moving average of $0.94 and a two-hundred day simple moving average of $0.94.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. XTX Topco Ltd raised its position in shares of RenovoRx by 58.6% during the 4th quarter. XTX Topco Ltd now owns 50,140 shares of the company’s stock worth $42,000 after purchasing an additional 18,525 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of RenovoRx in the 2nd quarter valued at approximately $98,000. Citadel Advisors LLC purchased a new position in shares of RenovoRx during the 3rd quarter worth approximately $154,000. Wealthspire Advisors LLC purchased a new position in shares of RenovoRx during the 4th quarter worth approximately $212,000. Finally, Geode Capital Management LLC boosted its position in shares of RenovoRx by 9.9% during the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after purchasing an additional 31,730 shares during the period. Institutional investors and hedge funds own 3.10% of the company’s stock.

Key Headlines Impacting RenovoRx

Here are the key news stories impacting RenovoRx this week:

• Positive Sentiment: HC Wainwright raised several earnings estimates for RenovoRx, including FY2026 and multiple quarterly forecasts, while reiterating a Buy rating and $3.00 price target. Higher forward EPS estimates can signal improving outlook and support the stock. HC Wainwright estimate updates
• Positive Sentiment: The company announced it will present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20, which may increase investor attention and provide a platform for management to discuss strategy and milestones. Alliance Global Partners showcase announcement
• Neutral Sentiment: The Q1 2026 earnings transcript is now available, giving investors more detail on management’s comments, but it does not by itself change fundamentals unless new guidance or strategy updates emerge. Q1 2026 earnings transcript
• Neutral Sentiment: Recent insider-trading news indicated CEO Shaun Bagai bought $0 of RNXT stock, which is not a strong signal either way but may have tempered enthusiasm for some traders. Insider trading news
• Negative Sentiment: Despite improved estimates, RenovoRx is still expected to remain unprofitable in the near term, with consensus full-year EPS estimates still negative. That ongoing losses can limit upside in the stock. Consensus earnings outlook

RenovoRx Company Profile

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.